



# Drug Discovery Toxicology Specialty Section



## Officers

### President

Peter Newham

### Vice President

Howard Mellor

### Vice President-Elect

Dinah Lee Misner

### Secretary/Treasurer

Marie Lemper

### Past President

Ray Kemper

### Councillors

Anthony Bahinski

Jennifer Cohen

### Student Rep

Guncha Taneja

### Postdoctoral Representative

Pankajini Mallick

Our mission: Provide a forum for discussion of emerging technologies, predictive toxicology, safety pharmacology, target validation, investigative toxicology and the application of safety assessment in a discovery research environment.

## How do we promote drug discovery toxicology?

- Provide networking opportunities for current and future discovery toxicologists.
- Sponsoring or endorsing sessions at SOT to highlight excellence in discovery toxicology, high quality science and topical timeliness.
- Recognize outstanding student and postdoctoral trainees in drug discovery toxicology via the Emil A. Pfitzer award.
- Organizing and running educational webinars covering key areas of relevance to the application of discovery toxicology.

## Announcing our new annual science competition!!

### Drug discovery toxicology paper of the year award

A recently published (or accepted) paper reporting exceptional scientific insight or progress in the field of drug discovery toxicology

- Plaque of recognition
- Financial award
- Invitation to present work at our annual reception

- First author must be a DDTSS member
- Paper must be published (or accepted) in 2018
- Submissions to our secretary by Dec 31<sup>st</sup> 2018
- Further details will follow in our newsletter

## List of Past Presidents

Ray Kemper	2016
Dan Kemp	2015
Andrew Olharski	2014
Yvonne Will	2013
John Wisler	2012
Craig Thomas	2011
Cindy Ashfari	2010
John Davis	2009
Kyle Kolaja	2008
Drew Badger	2004-2007

## Recent & Planned Drug Discovery Toxicology Specialty Section Webinars

- “Advanced cell systems for toxicological profiling: 3D models, microtissues and microphysiological systems”, presented by Matt Wagoner (AstraZeneca)
- “Use of different physico-chemical properties, DMPK, and in vitro toxicity parameters for assessing risk of hepatotoxicity”, given by Will Proctor (Genentech)
- Immuno-Oncology Special Feature:
  - Nonclinical Safety Assessment of Checkpoint Inhibitors and Costimulatory Agonists
  - Safety Assessment of Immune Cell-Based Therapies for Immuno-Oncology
  - Evolution of Safety Assessment for T Cell-Dependent Bispecific Molecules
  - Presenters: Helen Haggerty, (Bristol-Myers Squibb), Rodney Prell (Genentech), Tim MacLachlan, (Novartis Institutes of Biomedical Research)
  - Drug Discovery Toxicology Overview, given by Brandon Jeffy (Takeda)
- Planned:
  - Precise Genome Editing

Please attend our DDTSS-sponsored sessions and come meet us at the reception  
(Tues. 6 – 7:30pm)

